Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
17
Views
1
CrossRef citations to date
0
Altmetric
Review

The drug-based pipeline against restenosis

Pierre-Frédéric Keller Montreal Heart Institute, 5000 Belanger Street, Montreal, H1T 1C8 Canada. [email protected]
,
Reda Ibrahim Montreal Heart Institute, 5000 Belanger Street, Montreal, H1T 1C8 Canada. [email protected]
&
Jean-Claude Tardif Montreal Heart Institute, 5000 Belanger Street, Montreal, H1T 1C8 Canada. [email protected]
Pages 67-86 | Published online: 22 Apr 2005

Bibliography

  • SMITH SC, JR, DOVE JT, JACOBS AK et al.: ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J. Am. Coll. Cardiol. (2001) 37(8):2215–2239.
  • TOPOL EJ, LEYA F, PINKERTON CA et al.: A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl. J. Med. (1993) 329(4):221–227.
  • SCHUHLEN H, KASTRATI A, MEHILLI J et al.: Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am. Heart J. (2004) 147(2):317–322.
  • SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N EngL J. Med. (1994) 331(8):489–495.
  • LEGRAND VM, SERRUYS PW, UNGER F et al.: Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation (2004) 109(9):1114–1120.
  • WEINTRAUB WS: Evaluating the cost of therapy for restenosis: considerations for brachytherapy. Int. J. Radiat. OncoL Biol. Phys. (1996) 36(0949–958.
  • FATTORI R, PIVA T: Drug-eluting stents in vascular intervention. Lancet (2003) 361(9353):247–249.
  • KONG DF, EISENSTEIN EL, SKETCH MH JR et al.: Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am. Heart J. (2004) 147(3):449–456.
  • SIROIS MG, SIMONS M, EDELMAN ER: Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation (1997) 95(3):669–676.
  • LINDNER V, REIDY MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. NatL Acad. Sci. USA (1991) 88(9):3739–3743.
  • PANDA D, KUNDU GC, LEE BI et el.: Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. NatL Acad. Sci. USA (1997) 94(17):9308–9313.
  • IWASHINA M, SHICHIRI M, MARUMO F, HIRATA Y: Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation (1998) 98(12):1212–1218.
  • WANG BY, CANDIPAN RC, ARJOMANDI M et al.: Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. (1996) 28(6):1573–1579.
  • JANSSENS S, FLAHERTY D, NONG Z et al.: Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation (1998) 97(13):1274–1281.
  • CHENG L, MANTILE G, PAULY R et al: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation (1998) 98(20):2195–2201.
  • SIEREVOGEL MJ, PASTERKAMP G, VELEMA E et al.: Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation: an intravascular ultrasound study in the pig. Circulation (2001) 103(2):302–307.
  • SCHWARTZ L, BOURASSA MG, LESPERANCE J et al.: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N EngL J. Med. (1988) 318(20:1714–1719.
  • MEHTA SR, YUSUF S, PETERS RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358(9281):527–533.
  • Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation (1999) 100(8):799–806.
  • GIBSON CM, GOEL M, COHEN DJ et al.: Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J. Am. Coll. Cardiol. (1998) 32(1):28–34.
  • LINCOFF AM, TCHENG JE, ELLIS S: Randomized trials of platelet glycoprotein inhibiton with integrelin for prevention of restenosis following coronary intervention. The IMPACT-Angiographic Substudy. Circulation (1995) 92:1–607.
  • HONG YJ, JEONG MH, KIM W et al: Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am. J. Cardiol. (2004) 94(01050–1054.
  • BRACK MJ, RAYS, CHAUHAN A et al.: The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J. Am. Coll. Cardiol. (1995) 26(4):947–954.
  • WILENSKY RI,, TANGUAY JF, ITO S et al.: Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. Am. Heart J. (2000) 139(6):1061–1070.
  • MENEVEAU N, SCHIELE F, GROWER G et al.: Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS Trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study. Eur. Heart J. (2000) 21(21):1767–1775.
  • TEN BERG JM, KELDER JC, SUTTORP MJ, VERHEUGT FW, PLOKKER HW: A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS). Am. Heart J. (2003) 145(1):58–65.
  • CAIRNS JA, GILL J, MORTON B et al: Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation (1996) 94(7):1553–1560.
  • FINGERLE J, FAULMULLER A, MULLER G et al.: Pituitary factors in blood plasma are necessary for smooth muscle cell proliferation in response to injury in vivo. Arterioscler. Thromb. (1992) 12(12):1488–1495.
  • EMANUELSSON H, BEATT KJ, BAGGER JP et al.: Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation (1995) 91(6):1689–1696.
  • LIU MW, ROUBIN GS, ROBINSON KA et al.: Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation (1990) 81(3):1089–1093.
  • SERRUYS PW, FOLEY DP, PIEPER M, KLEIJNE JA, DE FEYTER PJ: The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur. Heart J. (2001) 22(20):1938–1947.
  • TAMAI H, KATOH O, SUZUKI S et al: Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am. Heart J. (1999) 138(5 Pt 1):968–975.
  • TAMAI H, KATOH K, YAMAGUCHI T et al.: The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am. Heart J. (2002) 143(3):506–513.
  • HOLMES DR, JR., SAVAGE M, LABLANCHE JM et al.: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2002) 106(10):1243–1250.
  • SCHNYDER G, ROFFI M, FLAMMERY, PIN R, HESS OM: Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur. Heart J. (2002) 23(9):726–733.
  • GENSER D, PRACHAR H, HAUER R et al.: Relation of homocysteine, vitamin 89(5):495–499.
  • ZAIRIS MN, AMBROSE JA, MANOUSAKIS SJ et al.: The impact of lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J. Am. Coll. Cardiol. (2002) 40(8):1375–1382.
  • SCHNYDER G, ROFFI M, PIN R et al: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N EngL J. Med. (2001) 345(22):1593–1600.
  • SCHNYDER G, ROUVINEZ G: Total plasma homocysteine and restenosis after percutaneous coronary angioplasty: current evidence. Ann. Med. (2003) 35(3):156–163.
  • SCHNYDER G, ROFFI M, FLAMMERY et al.: Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am. J. Cardiol. (2003) 91(10):1265–1269.
  • SCHNYDER G, ROFFI M, FLAMMERY, PIN R, HESS OM: Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA (2002) 288(8):973–979.
  • LANGE H, SURYAPRANATA H, DE LUCA G et al.: Folate Therapy and In-Stent Restenosis after Coronary Stenting. N EngL J. Med. (2004) 350(20:2673–2681.
  • DESMET W, VROLIX M, DE SCHEERDER I et al.: Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation (1994) 89(1):385–392.
  • FAXON DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J. Am. Coll. Cardiol. (1995) 25(2):362–369.
  • PETERS S, GOTTING B, TRUMMEL M, RUST H, BRATTSTROM A: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J. Invasive Cardiol. (2001) 13(2):93–97.
  • SERRUYS PW, KLEIN W, TIJSSEN JP et al.: Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation (1993) 88(4 Pt 1):1588–1601.
  • KYRIAKIDES ZS, PSYCHARI SN, KOLETTIS TM et al.: Usefulness of endothelin(A) receptor antagonists for the prevention of in-stent restenosis in patients with stable angina pectoris or silent myocardial ischemia. Am. J. Cardiol. (2003) 91(4):476–479.
  • DOUGLAS JS, WEINTRAUB WS, HOLMES D: Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. Clin. Cardiol. (2003) 26(10):451–454.
  • LABLANCHE JM, GROLLIER G, LUSSON JR et al.: Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem. Circulation (1997) 95(1):83–89.
  • VERSACI F, GASPARDONE A, TOMAI F et al.: Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J. Am. Coll. Cardiol. (2002) 40(11):1935–1942.
  • TARDIF JC, COTE G, LESPERANCE J et al.: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N EngL j Med. (1997) 337(6):365–372.
  • RODES J, COTE G, LESPERANCE J et al.: Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 97(5):429–436.
  • COTE G, TARDIF JC, LESPERANCE J et al.: Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation (1999) 99(1):30–35.
  • YOKOI H, DAIDA H, KUWABARA Y et al.: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J. Am. Coll. Cardiol. (1997) 30(4):855–862.
  • REINOEHL J, FRANKOVICH D, MACHADO C et al.: Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am. Heart J. (1996)131(6):1184–1191.
  • TARDIF JC, GREGOIRE J, LAVOIE MA L'ALLIER PL: Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies. Curr. Opin. LipidoL (2003) 14(6):615–620.
  • MENG CQ, SOMERS PK, RACHITA CL et al.: Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg. Med. Chem. Lett (2002) 12(18):2545–2548.
  • SUNDELL CL, SOMERS PK, MENG CQ et al.: AGI-1067: A Multifunctional Phenolic Antioxidant, Lipid Modulator, Anti-Inflammatory and Antiatherosclerotic Agent. J. PharmacoL Exp. Ther. (2003) 305(3):1116–1123.
  • TARDIF JC, GREGOIRE J, SCHWARTZ L et al.: Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 107(4):552–558.
  • TARDIF JC: Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. J. Cardiol. (2003) 91 (3A):41A–49A.
  • WAKEYAMA T, OGAWA H, IIDA H et al: Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ. J. (2003) 67(6):519–524.
  • JORGENSEN B, SIMONSEN S, ENDRESEN K et al: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J. Am. Coll. Cardiol. (2000) 35(3):592–599.
  • BESTEHORN HP, NEUMANN FJ, BUTTNER HJ et al: Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. J. Am. Coll. Cardiol. (2004) 43(12):2160–2165.
  • SERRUYS PW, FOLEY DP, JACKSON G et al: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. (1999) 20(1):58–69.
  • SERRUYS PW, DE FEYTER P, MACAYA C et al: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. /AMA (2002) 287(24):3215–3222.
  • KLEEMANN A. ECKERT S, VON ECKARDSTEIN A et al: Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur. Heart J. (1999) 20(19):1393–1406.
  • WALTER DH, SCHACHINGER ELSNER M et al: Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol. (2000) 85(8):962–968.
  • PRATT F, MOROCUTTI G, BERNARDI G et al: The extent of late in-stent neointima formation is modified by treatment with pravastatin: a preliminary study with intravascular ultrasound. Ital. Heart J. (2002) 3(8):455–461.
  • BUNCH TJ, MUHLESTEIN JB, ANDERSON JL et al: Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. Am. J. Cardiol. (2002) 90(3):299–302.
  • SCHELLER B, SPECK U, ROMEIKE B et al.: Contrast media as carriers for local drug delivery: Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur. Heart J. (2003) 24(15):1462–1467.
  • KOSTER R, VIELUF D, KIEHN M et al: Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet (2000) 356(9245):1895–1897.
  • DI MARIO C, GRUBE E, NISANCI Y et al.: MOONLIGHT: a controlled registry of an iridium oxide-coated stent with angiographic follow-up. Int. J. Cardiol. (2004) 95(2-3):329–331.
  • CURCIO A, TORELLA D, CUDA G et al.: Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Am. J. PhysioL Heart Circ. PhysioL (2004) 286(3):H902–908.
  • ANTONIUCCI D, BARTORELLI A, VALENTI R et al: Clinical and angiographic outcome after coronary arterial stenting with the carbostent. Am. J. Cardiol. (2000) 85(7):821–825.
  • TAMAI H, IGAKI K, KYO E et al.: Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation (2000) 102(4):399–404.
  • VOGT F, STEIN k RETTEMEIER G et al: Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur. Heart J. (2004) 25(15):1330–1340.
  • ZILBERMAN M, SCH WADE ND, EBERHART RC: Protein-loaded bioresorbable fibers and expandable stents: Mechanical properties and protein release. Biomed. Mater. Res. (2004) 69B(1):1–10.
  • HEUBLEIN B, ROHDE R, KAESE V et al: Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart (2003) 89(6):651–656.
  • DIM C, GRIFFITHS H, GOKTEKIN O et al: Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol. (2004) 17(6):391–395.
  • FINKELSTEIN A, MCCLEAN D, KAR S et al: Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation (2003) 107(5):777–784.
  • BOEHM M, NABEL EG: Cell cycle and cell migration: new pieces to the puzzle. Circulation (2001) 103(24):2879–2881.
  • SHERR CJ, ROBERTS JM: CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev. (1999) 13(12):1501–1512.
  • PERLMAN H, SUZUKI E, SIMONSON M, SMITH RC, WALSH K: GATA-6 induces p21(Cip 1) expression and G1 cell cycle arrest. J. Biol. Chem. (1998) 273(22):13713–13718.
  • SMITH RC, BRANELLEC D, GORSKI DH et al: p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. (1997) 11(13):1674–1689.
  • GUO M, HAY BA: Cell proliferation and apoptosis. Curr. Opin. Cell Biol. (1999) 11(6):745–752.
  • KOEPP DM, HARPER JW, ELLEDGE SJ: How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell (1999) 97(4):431–434.
  • SIMONS M, ROSENBERG RD: Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. (1992) 70(0835–843.
  • SPEIR E, EPSTEIN SE: Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation (1992) 86(2):538–547.
  • SHI Y, FARD A, GALEO A et al.: Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation (1994) 90(2):944–951.
  • POON M, MARX SO, GALLO R et al: Rapamycin Inhibits Vascular Smooth Muscle Cell Migration. J. Clin. Invest. (1996) 98(142277–2283.
  • MARX SO, JAYARAIVIAN T, GO LO, MARKS AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. (1995) 76(3):412–417.
  • GALLO R, PADUREAN A, JAYARAMAN T et al.: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 99(10:2164–2170.
  • MARX SO, MARKS AR: Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis. Circulation (2001) 104(8):852–855.
  • LUO Y, MARX SO, KIYOKAWA H et al: Rapamycin resistance tied to defective regulation of p27Kipl. MoL Cell. Biol. (1996) 16(12):6744–6751.
  • BRARA PS, MOUSSAVIAN M, GRISE MA et al.: Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation (2003) 107(13):1722–1724.
  • HAUSLEITER J, KASTRATI A, MEHILLI J et al.: Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation (2004) 110(7):790–795.
  • WAKSMAN R, AJANI AE, PICHARD AD et al.: Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J. Am. Coll. CardioL (2004) 44(7):1386–1392.
  • MORICE M-C, SERRUYS PW, SOUSA JE et al.: A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. N EngL J. Med. (2002) 346(23):1773–1780.
  • MOSES JW, LEON MB, POPMA JJ et al: Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. N EngL J. Med. (2003) 349(101315–1323.
  • SCHOFER J, SCHLUTER M, GERSHLICK AH et al.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 362(9390):1093–1099.
  • DEGERTEKIN M, ARAMPATZIS CA, LEMOS PA et al.: Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am. J. CardioL (2004) 93(7):826–829.
  • SERRUYS PW, LEMOS PA, VAN HOUT BA: Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart (2004) 90(9):995–998.
  • GRUBE E, BUELLESFELD L: Everolimus for stent-based intracoronary applications. Rev. Cardiovasc. Med. (2004) 2\(Supp1.5):53–8.
  • REGAR E, LEMOS PA, SAIA F et al: Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am. J. CardioL (2004) 93(10):1271–1275.
  • MUNI NI, GROSS TP: Problems with drug-eluting coronary stents-the FDA perspective. N EngL J. Med. (2004) 351(10:1593–1595.
  • HERDEG C, OBERHOFF M, BAUMBACH A et al: Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. CardioL (2000) 35(7):1969–1976.
  • FARB A, HELLER PF, SHROFF S et al: Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation (2001) 104(4):473–479.
  • HELDMAN AW, CHENG L, JENKINS GM et al: Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation (2001) 103(18):2289–2295.
  • SIGNORE PE, MACHAN LS, JACKSON JK et al.: Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J. Vasc. Interv. RadioL (2001) 12(1):79–88.
  • PARKS-J, SHIM WH, HO DS et al: A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis. N Engl. J. Med. (2003) 348(161:1537–1545.
  • MINTZ GS, TINANA A, HONG M-K et al: Impact of Preinterventional Arterial Remodeling on Neointimal Hyperplasia After Implantation of (Non-Polymer-Encapsulated) Paclitaxel-Coated Stents: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation (2003) 108(11):1295–1298.
  • LANSKY AJ, COSTA RA, MINTZ GS et al: Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial. Circulation (2004) 109(16):1948–1954.
  • GERSHLICK A, DE SCHEERDER I, CHEVALIER B et al: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation (2004) 109(4):487–493.
  • GRUBE E, SILBER S, HAUPTMANN KE et al: TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation (2003) 107(1):38–42.
  • COLOMBO A, DRZEWIECKI J, BANNING A et al: Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions. Circulation (2003) 108(7):788–794.
  • TANABE K, SERRUYS PW, GRUBE E et al: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation (2003) 107(4):559–564.
  • STONE GW, ELLIS SG, COX DA et al: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N EngL J. Med. (2004) 350(3):221–231.
  • GRUBE E, LANSKY A, HAUPTMANN KE et al.: High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J. Am. Coll. CardioL (2004) 44(7):1368–1372.
  • ROBINSON KA, CHRONOS NAF, JOYAL J: Actinomycin-D drug-eluting stents preserve lumen size and inhibits fibrocellular neointima in pig coronary arteries. Circulation (2001) 104 (Suppl.
  • SERRUYS PW, ORMISTON JA, SIANOS G et al.: Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J. Am. Coll. CardioL (2004) 44(7):1363–1367.
  • HAYNES MP, LI L, RUSSELL KS, BENDER JR: Rapid vascular cell responses to estrogen and membrane receptors. VascuL PharmacoL (2002) 38(2):99–108.
  • KOH KK: Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc. Res. (2002) 55(4):714–726.
  • PARE G, KRUST A, KARAS RH et al.: Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res. (2002) 90(141087–1092.
  • ZHU Y, BIAN Z, LU P et al.: Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (2002) 295(5554):505–508.
  • CHANDRASEKAR B, TANGUAY JF: Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model. J. Am. Coll. CardioL (2000) 36(0:1972–1978.
  • ABIZAID A, ALBERTAL M, COSTA MA et al.: First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J. Am. Coll. CardioL (2004) 43(6):1118–1121.
  • LIU X, HUANG Y, HANET C et al.: Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc. Interv. (2003) 60(2):172–178; discussion 179.
  • LIU X, CHEVALIER, B. GLATT B: Batimastat (BB-94) anti-restenosis trial utilizing the BiodivYsio local drug delivery PC-stent (BRILLIANT-EU-trial). Presented at the ESC Congress; August 30-September 3, 2003; Vienna, Austria. (2003):1496.
  • USUI M, MIYAGI M, FUKASAWA S et al.: A first trial in the clinical application of photodynamic therapy for the prevention of restenosis after coronary-stent placement. Lasers Surg-. Med. (2004) 34(3):235–241.
  • BRAUN-DULLAEUS RC, MANN MJ, DZAU VJ: Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation (1998) 98(1):82–89.
  • HUNTER T: Oncoprotein networks. Cell (1997) 88(3):333–346.
  • DZAU VJ, BRAUN-DULLAEUS RC, SEDDING DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. (2002) 8(11):1249–1256.
  • QUINCOCES AF, LEON J: Serum growth factors up-regulate H-ras, K-ras, and N-ras proto-oncogenes in fibroblasts. Cell Growth Differ. (1995) 6(3):271–279.
  • HUCKLE WR, EARP HS: Regulation of cell proliferation and growth by angiotensin II. Prog-. Growth Factor Res. (1994) 5(2):177–194.
  • DAKSIS JI, LU RY, FACCHINI LM, MARHIN WW, PENN LJ: Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene (1994) 9(12):3635–3645.
  • PHUCHAREON J, TOKUHISA T: Deregulated c-Fos/AP-1 modulates expression of the cyclin and the cdk gene in splenic B cells stimulated with lipopolysaccharide. Cancer Lett. (1995) 92(2):203–208.
  • STEINER P, PHILIPP A, LUKAS J et al.: Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. Embo. J. (1995) 14(19):4814–4826.
  • LIU JJ, CHAO JR, JIANG MC et al.: Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. MoL Cell. Biol. (1995) 15(7):3654–3663.
  • BENNETT MR, ANGLIN S, MCEWAN JR et al.: Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. (1994) 93(2):820–828.
  • KIPSHIDZE N, KEANE E, STEIN D et al.: Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv (2001) 54(2):247–256.
  • KIPSHIDZE NN, KIM HS, IVERSEN P et al.: Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model./ Am. Coll. CardioL (2002) 39(10):1686–1691.
  • KIPSHIDZE NN, PORTER TR, DANGAS G et al.: Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovascular Radiat. Med. (2003) 4(3):152–159.
  • KUTRYK MJB, FOLEY DP, VAN DEN BRAND M et al.: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: Results of the randomized investigation by the thoraxcenter of antisense dna using local delivery and ivus after coronary stenting (ITALICS) trial. J. Am. Coll. CardioL (2002) 39(2):281–287.
  • BUELLESFELD L, GRUBE E: ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz (2004) 29(2):167–170.
  • KIPSHIDZE N, DANGAS G, TSAPENKO M et al.: Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J. Am. Coll. CardioL (2004) 44(4):733–739.
  • KONG D, MELO LG, GNECCHI M et al.: Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation (2004) 110(14):2039–2046.
  • KUTRYK MJ, VAN DORTMONT LM, DE CROM RP et al.: Seeding of intravascular stents by the xenotransplantation of genetically modified endothelial cells. Semin. Interv. CardioL (1998) 3(3-4):217–220.
  • GOMES D, LOUEDEC L, PLISSONNIER D et al.: Endoluminal smooth muscle cell seeding limits intimal hyperplasia. j Vasc. Surg-. (2001) 34(4):707–715.
  • CASTRONUOVO JJ, JR., GUSS SB, MYSH D et al.: Cytokine therapy for arterial restenosis: inhibition of neointimal hyperplasia by gamma-interferon. Cardiovasc. Surg-. (1995) 3(5):463–468.
  • KIPSHIDZE N, MOUSSA I, NIKOLAYCHIK V et al.: Influence of Class I interferons on performance of vascular cells on stent material in vitro. Cardiovasc. Radiat. Med. (2002) 3(2):82–90.
  • HAYASHI S, WATANABE N, NAKAZAWA K et al.: Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation (2000) 102(101710–1717.
  • GOTOH R, SUZUKI J, KOSUGE H et al.: E-selectin blockade decreases adventitial inflammation and attenuates intimal hyperplasia in rat carotid arteries after balloon injury. Arterioscler. Thromb. Vase. Biol. (2004) 24(11):2063–2068.

Websites

  • http://www.tctmd.com/display/expert/pdf/ 71172/Grube-FUTURE.pdf GRUBE E: Clinical results from FUTURE I and futurw plans. (2003).
  • http://www.tctmd.com/display/expert/pdf/ 80013/FUTURE.pdf GRUBE E: FUTURE II: Multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. Transcatheter Cardiovascular Therapeutics (TCT) (2003).
  • http://www.tctmd.com/display/expert/pdf/ 47017/Heldman-PATENCY.pdf HELDMAN AW: The PATENCY Pilot Trial: First report/PATENCY PAclitaxel-coated LogicsTENt for CYtostatic prevention of restenosis. A roll-in feasibility study. Transcatheter Cardiovascular Therapeutics (TCT). (2002).
  • http://www.crtonline.org/documents/ TAXUS°/020V1%20-°/020Clinical-short_Grube.ppt GRUBE E: TAXUS VI A Randomized Trial of Moderate Rate Release Polymer-Based Paclitaxel-Eluting TAXUS Stent for the Treatment of Longer Lesions. (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.